Baicalein Exerts Therapeutic Effects against Endotoxin-Induced Depression-like Behavior in Mice by Decreasing Inflammatory Cytokines and Increasing Brain-Derived Neurotrophic Factor Levels

Inflammation plays an important role in the pathophysiology of depression. This study aims to elucidate the antidepressant effect of baicalein, an anti-inflammatory component of a traditional Chinese herbal medicine (Scutellaria baicalensis), on lipopolysaccharide (LPS)-induced depression-like behavior in mice, and to investigate the underlying mechanisms. In vitro, baicalein exhibited antioxidant activity and protected macrophages from LPS-induced damage. The results of the tail suspension test and forced swimming test (tests for despair potential in mice) showed the antidepressant effect of baicalein on LPS-treated mice. It also substantially decreased the production of pro-inflammatory cytokines, including IL-6, TNF-α, MCP-1, and eotaxin, elicited by LPS in the plasma. Baicalein downregulated NF-κB-p65 and iNOS protein levels in the hippocampus, demonstrated its ability to mitigate neuroinflammation. Additionally, baicalein increased the levels of the mature brain-derived neurotrophic factor (mBDNF) in the hippocampus of LPS-treated mice, and elevated the ratio of mBDNF/proBDNF, which regulates neuronal survival and synaptic plasticity. Baicalein also promoted the expression of CREB, which plays a role in a variety of signaling pathways. In summary, the findings of this study demonstrate that the administration of baicalein can attenuate LPS-induced depression-like behavior by suppressing neuroinflammation and inflammation induced by the peripheral immune response.


Introduction
Depression is a common mental illness in which an individual persistently experiences sadness and loss of pleasure for long durations, and has difficulty participating in normal routines. In modern society, lifestyles are associated with chronic stress, which commonly leads to the dysregulation of the Hypothalamic-Pituitary-Adrenal (HPA) axis and elevated glucocorticoid hormone levels. Previously, the occurrence of depression and neuronal damage have been observed in rodents with chronic exposure to glucocorticoids [1,2]. According to the 2017 World Health Organization (WHO) report, 322 million people are estimated to suffer from depression, which has become the leading cause of disability, and contributes to disease burden globally [3].

1.
Group I was treated with normal saline twice with a gap of 1 h between treatments. This group was considered the normal control group.
A control group treated with baicalein, which may show the effect of baicalein on healthy animals, was not included because the goal of this study was to evaluate the therapeutic effect of this compound. The determined doses of baicalein (3 mg/kg, i.p.) and LPS (5 mg/kg, i.p.) were based on previous studies [29,32,33].
In order to know if baicalein could inhibit inflammation when LPS commenced its effects, baicalein was injected 1 h after LPS administration. Behavioral evaluations were performed 24-27 h after LPS administration (23-26 h after baicalein administration). Then, the mice were sacrificed the same day that the final behavioral test was performed. The time between the baicalein administration and sacrifice was about 26 h; this was almost the same for all animals.

Behavioral Evaluations
As the depression-like behaviors can be observed 24 h post peripheral LPS administration in mice [34,35], behavioral tests were conducted with animals in all groups 24-27 h after LPS administration. The forced swimming test (FST) and tail suspension test (TST) are widely used to assess depression-like behavior in rodent models [36,37]. The duration of immobility was measured to evaluate the potential for behavioral despair.
In this study, different batches of mice were used for TST and FST. Each mouse underwent either FST or TST. Half of the total mice were randomly assigned into three groups for different treatments; then, the mice underwent TST on the same day. Moreover, the other half underwent FST; however, TST and FST were not conducted on the same day. Each test was performed at almost the same time after baicalein administration.

Forced Swimming Test (FST)
Mice were individually placed in an acrylic cylinder (height: 40 cm, diameter: 18 cm) filled with 30 cm of water (25 ± 1 • C) to prevent them from touching the bottom. The activity of each mouse was videotaped during a 6 min swimming session. Following the session, the mice were towel-dried and placed under a 60 W bulb for further drying. The water in the acrylic cylinder was changed after each trial. Immobility was defined as the mice floating in the water without struggling and only making gentle movements to keep their head above the water. The total immobility time was measured during the 5 min of the swimming session. The FST recordings were analyzed using the commercial video tracking software SMART 3.0 (Panlab Harvard Apparatus, Barcelona, Spain).

Tail Suspension Test (TST)
The mice were individually suspended 30 cm above the floor of the suspension box. The tape securely adhered the tail of the mouse to the suspension bar. Each mouse was suspended in the middle of the compartment. The contact with the walls was disabled, and the activity of the mice was videotaped during a 6 min session. At the end of each session, the mouse was returned to the home cage, and the apparatus was wiped thoroughly. Immobility was defined as the observation of a completely motionless, suspended animal. The total immobility time was measured during the 5 min of the session. TST analysis was also performed using SMART 3.0.

Cytokine Assessment
After the final behavioral test, the mice were anesthetized with 3% isoflurane (Panion & BF Biotech, Taoyuan, Taiwan), and blood samples were collected from the hearts. The blood samples were centrifuged at 3000 rpm for 10 min at 4 • C to obtain the plasma. Concentrations of circulating cytokines, including IL-6, IL-1β, IL-10, eotaxin, monocyte chemoattractant protein-1 (MCP-1), and TNF-α, were assessed using the MILLIPLEX Multi-Analyte Profiling (MAP) Mouse Cytokine/Chemokine Kit (Millipore, Billerica, MA, USA) on a Luminex platform.

Assessment of in Vivo Anti-Oxidation Ability
Mouse plasma of all groups was used to detect the antioxidant activities against hydrogen peroxide using a chemiluminescence (CL) analysis system. The CL signal emitted from the mixture containing 200 µL of plasma and 500 µL of luminol was measured with an ultrasensitive CL analyzer (CLD-110; Tohoku Electronic Industrial, Japan) as the baseline level. Then, 100 µL of 0.03% H 2 O 2 (Nihon Shiyaku Reagent, Tokyo, Japan) was loaded into the mixture for continuous signal recording. Total CL counts in 5 min were calculated by integrating the area under the curve. The results are expressed as CL counts (10 s) −1 . The assay was carried out in duplicate for each sample.

Western Blot Analysis
The mice were anesthetized and euthanized by cervical dislocation after the final behavioral test. The mouse hippocampi were dissected and homogenized in RIPA buffer containing protease and phosphatase inhibitors. Tissue lysates were centrifuged for 10 min at 4 • C, and the supernatants were collected for the protein concentration assay, which was conducted using a BCA kit (Bio-Rad Laboratories, Hercules, CA, USA). SDS-PAGE electrophoresis was used to separate proteins, and the proteins were subsequently transferred onto a PVDF membrane. Subsequently, the membranes were incubated in solutions containing primary antibodies at 4 • C overnight. The primary antibodies used in this study were anti-iNOS (GTX130246, GeneTex, Irvine, CA, USA), anti-BDNF (ab226843, Abcam, Cambridge, MA, USA), anti-NF-κB p65 (8242S, Cell Signaling Technology, Beverly, MA, USA), anti-CREB (9197S, Cell Signaling Technology, Beverly, MA, USA), and GAPDH (sc-32233 Santa Cruz Biotechnology, Santa Cruz, CA, USA). After washing, the membranes were incubated with a horseradish peroxidase-conjugated (HRP) secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at room temperature. Finally, a chemiluminescent HRP substrate was used to visualize the protein bands.

Macrophage Viability Assay
Using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, which detects viable mitochondria in active cells, we examined the effect of baicalein on the viability of liver macrophages (Kupffer cells) (SCC119, Sigma-Aldrich Co., Saint Louis, Missouri, USA). Briefly, baicalein (1-100 µM) mixed with LPS was added to the medium, and the cells were incubated at 37 • C for 24 h. Then, MTT reagents were added to the medium and incubated for another 2 h. After discarding the medium, the cells were collected, and DMSO was added to dissolve the MTT formazan. The end color of the assay was analyzed by measuring the absorbance at 570 nm, which was proportional to the cell number. The assay was carried out in triplicate for each sample.

DPPH Radical Scavenging Assay
The free radical scavenging activity of baicalein was determined in vitro using the DPPH assay. Various concentrations of baicalein (5-1000 µM) were mixed with a methanol solution of DPPH and shaken vigorously. The mixture was then left in the dark for 30 min. The absorbance was measured at 517 nm, and the DPPH radical scavenging efficiency was calculated as follows: DPPH radical scavenging efficiency (%) = (1 − absorbance of sample/absorbance of control) × 100 (1) L-ascorbic acid was used as the standard. The experiment was performed in triplicate for each sample.

Statistical Analysis
Statistical analyses were performed using GraphPad Prism 6.0 (GraphPad Software Inc., San Diego, CA, USA). Data are presented as the mean ± SEM. Comparisons between two groups were performed using the Mann-Whitney U-test, and the results of the DPPH assay were analyzed using one-way ANOVA and Tukey's test. The Shapiro-Wilks test was adopted to detect the departure from normality. Levene's test was used to assess the homogeneity of variance across samples. Statistical significance was set at p < 0.05.

Baicalein Exhibits Antioxidant Activity in a Dose-Dependent Manner
The 2,2-diphenyl-1-picryl-hydrazyl-hydrate (DPPH) assay was performed in vitro to evaluate the antioxidant activities of baicalein. The higher the concentration of baicalein, the higher the antioxidant activity ( Figure 1).

DPPH Radical Scavenging Assay
The free radical scavenging activity of baicalein was determined in vitro u DPPH assay. Various concentrations of baicalein (5-1000 µM) were mixed with a nol solution of DPPH and shaken vigorously. The mixture was then left in the da min. The absorbance was measured at 517 nm, and the DPPH radical scaveng ciency was calculated as follows: DPPH radical scavenging efficiency (%) = (1 − absorbance of sample/absorbance of control) × 100 L-ascorbic acid was used as the standard. The experiment was performed in t for each sample.

Statistical Analysis
Statistical analyses were performed using GraphPad Prism 6.0 (GraphPad S Inc., San Diego, CA, USA). Data are presented as the mean ± SEM. Comparisons b two groups were performed using the Mann-Whitney U-test, and the results of th assay were analyzed using one-way ANOVA and Tukey's test. The Shapiro-W was adopted to detect the departure from normality. Levene's test was used to as homogeneity of variance across samples. Statistical significance was set at p < 0.0

Baicalein Exhibits Antioxidant Activity in a Dose-Dependent Manner
The 2,2-diphenyl-1-picryl-hydrazyl-hydrate (DPPH) assay was performed in evaluate the antioxidant activities of baicalein. The higher the concentration of b the higher the antioxidant activity ( Figure 1).

Baicalein Effectively Relieves LPS-Induced Damage in Liver Macrophages
According to our results, baicalein increased the viability of the macrophag and demonstrated effects against LPS at concentrations ranging from 1-10 µM (F

Baicalein Effectively Relieves LPS-Induced Damage in Liver Macrophages
According to our results, baicalein increased the viability of the macrophages alone and demonstrated effects against LPS at concentrations ranging from 1-10 µM ( Figure 2). Antioxidants 2022, 11, x FOR PEER REVIEW 6

Baicalein Treatment Mitigates LPS-Induced Depression-Like Behavior
Both behavioral tests, FST and TST, showed that the duration of immobility increa after intraperitoneal (i.p.) administration of LPS (5 mg/kg), compared with that obser in the control group. Treatment with baicalein (3 mg/kg, i.p.) 1 h after LPS administra significantly decreased the immobility duration, indicating that it could normalize dep sion-like behaviors induced by LPS ( Figure 3).

Baicalein Treatment Mitigates LPS-Induced Depression-like Behavior
Both behavioral tests, FST and TST, showed that the duration of immobility increased after intraperitoneal (i.p.) administration of LPS (5 mg/kg), compared with that observed in the control group. Treatment with baicalein (3 mg/kg, i.p.) 1 h after LPS administration significantly decreased the immobility duration, indicating that it could normalize depression-like behaviors induced by LPS (Figure 3).

Baicalein Treatment Mitigates LPS-Induced Depression-Like Behavior
Both behavioral tests, FST and TST, showed that the duration of immobility incr after intraperitoneal (i.p.) administration of LPS (5 mg/kg), compared with that obs in the control group. Treatment with baicalein (3 mg/kg, i.p.) 1 h after LPS administ significantly decreased the immobility duration, indicating that it could normalize d sion-like behaviors induced by LPS (Figure 3).  The time schedule of the study design (A). The control group was administrated with normal saline twice (at 0 h and 1 h). The LPS-treated group was administrated with saline instead of baicalein at 1 h. LPS-induced depression-like behavior was evaluated using the tail suspension test (B) and forced swimming test (C). Both tests show that immobility duration increased after administration of LPS (5 mg/kg i.p.). Treatment with baicalein (3 mg/kg i.p.) 1 h after LPS administration markedly reduced the immobility duration and improved depression-like behaviors. Data are presented as means ± SEM. (n = 6) ** p < 0.01, *** p < 0.001.

Bacalien Mitigates the Increase in the Concentrations of Circulating Cytokines Induced by LPS
The concentrations of circulating cytokines, except those of IL-1β, increased significantly after the systemic challenge with LPS. The levels of IL-6, IL-10, eotaxin, monocyte chemoattractant protein-1 (MCP-1), and TNF-α were significantly downregulated in mice treated with both LPS and baicalein. The results showed that baicalein effectively moderated the peripheral immune response and inhibited inflammation (Figure 4). oxidants 2022, 11, x FOR PEER REVIEW 7 o administration markedly reduced the immobility duration and improved depression-like beh iors. Data are presented as means ± SEM. (n = 6) ** p < 0.01, *** p < 0.001.

Bacalien Mitigates the Increase in the Concentrations of Circulating Cytokines Induced by LPS
The concentrations of circulating cytokines, except those of IL-1β, increased sign cantly after the systemic challenge with LPS. The levels of IL-6, IL-10, eotaxin, monocy chemoattractant protein-1 (MCP-1), and TNF-α were significantly downregulated in m treated with both LPS and baicalein. The results showed that baicalein effectively mod ated the peripheral immune response and inhibited inflammation (Figure 4).

Baicalein Improves the Free Radical Scavenging Activity in Plasma
Compared with the control group, the plasma of LPS-treated mice exhibited reduc scavenging activity for H2O2, which was restored after baicalein administration. Baicale clearly demonstrated beneficial effects against LPS-induced oxidative stress under in vi conditions ( Figure 5).

Baicalein Improves the Free Radical Scavenging Activity in Plasma
Compared with the control group, the plasma of LPS-treated mice exhibited reduced scavenging activity for H 2 O 2 , which was restored after baicalein administration. Baicalein clearly demonstrated beneficial effects against LPS-induced oxidative stress under in vivo conditions ( Figure 5).

Treatment with Baicalein Significantly Reduces NF-κB-p65 and iNOS Protein Levels Elicited by LPS in the Hippocampus
To evaluate inflammation in the hippocampus, NF-κB-p65 and iNOS protein levels were measured via western blotting. As iNOS is the downstream target of NF-κB-p65 during the induction of the inflammatory response, both NF-κB-p65 and iNOS levels increased significantly in LPS-treated mice, but decreased significantly in the LPS-baicaleintreated mice ( Figure 6); hence, baicalein was shown to reduce neuroinflammation.

Treatment with Baicalein Significantly Reduces NF-κB-p65 and iNOS Protein Levels Elicited by LPS in the Hippocampus
To evaluate inflammation in the hippocampus, NF-κB-p65 and iNOS protein levels were measured via western blotting. As iNOS is the downstream target of NF-κB-p65 during the induction of the inflammatory response, both NF-κB-p65 and iNOS levels increased significantly in LPS-treated mice, but decreased significantly in the LPS-baicaleintreated mice ( Figure 6); hence, baicalein was shown to reduce neuroinflammation.

Treatment with Baicalein Significantly Reduces NF-κB-p65 and iNOS Protein Levels Elicited by LPS in the Hippocampus
To evaluate inflammation in the hippocampus, NF-κB-p65 and iNOS protein lev were measured via western blotting. As iNOS is the downstream target of NF-κB-p65 d ing the induction of the inflammatory response, both NF-κB-p65 and iNOS levels creased significantly in LPS-treated mice, but decreased significantly in the LPS-baicale treated mice ( Figure 6); hence, baicalein was shown to reduce neuroinflammation.

Baicalein Promotes the Protein Expression of BDNF and CREB Inhibited by LPS in the Hippocampus
To elucidate the antidepressant mechanism of baicalein, we examined the protein levels of BDNF and cAMP-response element-binding protein (CREB) in the hippocampus. The results showed that LPS inhibited the production of mBDNF ( Figure 7A,B) but not that of proBDNF. Baicalein treatment restored the level of mBDNF, and as a result, the ratio of mBDNF/proBDNF increased significantly ( Figure 7A-D). Compared with the control group, CREB levels changed slightly in LPS-treated mice. Interestingly, baicalein significantly promoted CREB protein expression, as observed in LPS-baicalein-treated mice ( Figure 7E-F).
Antioxidants 2022, 11, x FOR PEER REVIEW 9 of

Baicalein Promotes the Protein Expression of BDNF and CREB Inhibited by LPS in the Hippocampus
To elucidate the antidepressant mechanism of baicalein, we examined the prote levels of BDNF and cAMP-response element-binding protein (CREB) in the hippocampu The results showed that LPS inhibited the production of mBDNF ( Figure 7A,B) but n that of proBDNF. Baicalein treatment restored the level of mBDNF, and as a result, th ratio of mBDNF/proBDNF increased significantly ( Figure 7A-D). Compared with the co trol group, CREB levels changed slightly in LPS-treated mice. Interestingly, baicalein si nificantly promoted CREB protein expression, as observed in LPS-baicalein-treated mi ( Figure 7E-F).

Discussion
Anti-inflammatory treatments have been proposed as a therapeutic approach for d pression [38]. The anti-inflammatory effects of baicalein have been demonstrated in co junction with inflammation-related diseases [39]. Baicalein could suppress the release pro-inflammatory mediators, including TNF-α, IL-6, and iNOS, in RAW264.7 macr phages stimulated by LPS [40]. Based on these findings, we hypothesized that baicale might attenuate inflammatory responses and depression-like behaviors in mice. The r sults of this study confirmed our hypothesis. Baicalein exerted both anti-inflammato and antidepressant effects.
An increase in the levels of circulating pro-inflammatory cytokines synchronize with depressive behavior was observed in LPS-treated mice, as expected in our study. LP significantly induced the production of IL-6, TNF-α, eotaxin, and MCP-1 in the plasm (Figure 4). The increase in immobility duration in the TST and FST tests indicated th

Discussion
Anti-inflammatory treatments have been proposed as a therapeutic approach for depression [38]. The anti-inflammatory effects of baicalein have been demonstrated in conjunction with inflammation-related diseases [39]. Baicalein could suppress the release of pro-inflammatory mediators, including TNF-α, IL-6, and iNOS, in RAW264.7 macrophages stimulated by LPS [40]. Based on these findings, we hypothesized that baicalein might attenuate inflammatory responses and depression-like behaviors in mice. The results of this study confirmed our hypothesis. Baicalein exerted both anti-inflammatory and antidepressant effects.
An increase in the levels of circulating pro-inflammatory cytokines synchronized with depressive behavior was observed in LPS-treated mice, as expected in our study. LPS significantly induced the production of IL-6, TNF-α, eotaxin, and MCP-1 in the plasma (Figure 4). The increase in immobility duration in the TST and FST tests indicated the despair potency of the LPS-treated mice. These results are consistent with those of previous studies [31,41] (Figure 3). The LPS-treated mice were examined for inflammation along with depression after infection. Herbal medicines are typically administered for therapy after infection. Since baicalein is the main bioactive flavone of Scutellaria baicalensis Georgi, a traditional Chinese herbal medicine commonly used to treat inflammation, to test its therapeutic effect, baicalein was administered post LPS treatment (instead of pre-treatment) to mice in this study. The results demonstrate that baicalein administration significantly decreased the production of pro-inflammatory cytokines induced by LPS and normalized depression-like behaviors (Figures 3 and 4).
Peripherally produced pro-inflammatory cytokines can access the brain through the choroid plexus and the circumventricular organs, stimulate afferent fibers of the vagus nerve, and then transmit inflammatory signals to the brain [42]. In another study examining inflammatory injuries in mice, peripheral TNF-α could activate microglia and induce the infiltration of monocytes into the brain [43]. Activated microglia and monocytes are thought to strengthen neuroinflammatory processes in the brain [44]. Our results demonstrated that baicalein had a remarkable ability to inhibit the production of pro-inflammatory cytokines in plasma, including that of TNF-α ( Figure 4); therefore, it is reasonable to speculate that baicalein might indirectly modulate neuroinflammation.
Accumulating evidence suggests that the involvement of neuroinflammation in affective disorders is complicated and profound [45]. In this study, neuroinflammation was evaluated by measuring the protein levels of NF-κB-p65 and iNOS in the hippocampus. Consistent with a recent report demonstrating that the levels of NF-κB and proinflammatory cytokines (IL-1β and TNF-α) significantly increased in the hippocampus of LPS-treated mice [46], LPS induced neuroinflammation and the production of NF-κB-p65 and iNOS in the present study. It is not surprising that the administration of baicalein significantly reduced the production of both proteins ( Figure 6). NF-κB initiates the production and regulates inflammatory mediators, including iNOS, during neuroinflammation [47]. The reduction in the levels of iNOS prevents excessive NO production, which is cytotoxic to neurons and suppresses further inflammatory responses. Similarly, Du et al. demonstrated that baicalein treatment alleviated neuroinflammation and depression-like behavior in mice with experimentally induced autoimmune prostatitis (EAP) by inhibiting the NF-κB signaling pathway [48].
Downregulation of BDNF is associated with neuroinflammation in many brain disorders [20], which typically present with depression as a comorbidity. The relationship between BDNF and behavioral disorders has been demonstrated in many studies [49]. In this study, two types of active BDNF isoforms were examined: mature BDNF (mBDNF) and proBDNF ( Figure 7A), which elicit contrary effects by binding to their receptors. Briefly, mBDNF signaling leads to neuronal survival and synaptic plasticity, whereas proBDNF signaling enhances neuronal death and synaptic pruning [50]. In rodents, the balance between mature BDNF and proBDNF has been proven to play an important role in depressionlike behaviors induced by chronic unpredicted mild stress, and a decrease in the ratio of mBDNF/proBDNF could induce a reduction in the dendritic spine density of hippocampal neurons [51]. A strong relationship between BDNF, neural plasticity, and behavioral disorders has been demonstrated [52]. According to our results, LPS-induced production of mBDNF decreased significantly upon treatment with baicalein, and it seems that the production of proBDNF was not affected by LPS and baicalein. Baicalein reversed the LPS-induced reduction in the mBDNF/proBDNF ratio ( Figure 7A-D). Preventing the downregulation of mBDNF might lead to neuronal survival, and reversing the ratio of mBDNF/proBDNF might be beneficial in building synapses. Baicalein is likely to protect neurons in these ways and exert an antidepressant response.
To further understand BDNF signaling, the protein levels of CREB in the hippocampus were examined. When mBDNF binds to its preferential receptor, TrkB, it activates several signaling cascades, such as the mitogen-activated protein kinase (MAPK) pathway and the phosphatidylinositol 3-kinase (PI3K) pathway, and eventually, CREB is activated [53]. CREB promotes the expression of the BDNF gene. We found that baicalein could elevate the protein levels of CREB in LPS-stimulated mice ( Figure 7E,F), which might partially explain how baicalein inhibits the decrease in the production of mBDNF.
As a reactive oxygen species (ROS) molecule, H 2 O 2 may damage various biological processes via free radical oxidation. This study demonstrated that baicalein not only exhibited antioxidant activity in vitro (Figure 1) but also augmented the ability of mice to scavenge hydrogen peroxide in vivo ( Figure 5), thereby protecting against LPS-induced oxidative stress. Gunawardena et al. had previously demonstrated that hydrogen peroxide mediates pro-inflammatory cell-to-cell signaling [54]. The strengthening of scavenging activity for H 2 O 2 by baicalein is in line with the anti-inflammatory effects mentioned above.
Interestingly, we also observed that baicalein could mediate a reduction in the levels of IL-10 ( Figure 6F), which is usually categorized as an anti-inflammatory cytokine. This indicates that the anti-inflammatory effect of baicalein cannot be attributed to IL-10 activity. In contrast, because baicalein attenuated inflammatory responses, the need for IL-10 to maintain the balance of the immune response was reduced. Macrophages are members of the innate immune system and play a vital role in mediating the inflammatory response. LPS, a toxin and an activator of macrophages, demonstrates a remarkable reduction in macrophage viability. We also found that baicalein could increase the viability of macrophages in vitro (Figure 2), which plays a critical role in the initiation, maintenance, and resolution of inflammation. Baicalein thereby protected macrophages from endotoxin-induced damage.
However, depression is highly prevalent, and its pathogenesis is complicated. Many patients do not have an optimal response to first-line antidepressant drugs, which are primarily designed to increase the availability of monoamines. The findings of this study demonstrate that baicalein might be a potential therapeutic agent for depression owing to its antioxidant and anti-inflammatory properties.
Although we demonstrated the antidepressant and anti-inflammatory effects of baicalein, this study still has some limitations. Based on the 3Rs principle (replacement, reduction and refinement), the number of mice in each group was 6-8. This small number might have caused bias. Additionally, to rule out the influence of the estrus cycle, only males were used; this is also a limitation in this study as the results are not generalizable for both sexes.

Conclusions
Taken together, baicalein attenuated LPS-induced depression-like behavior, and the possible underlying mechanism might involve its anti-inflammatory effects, including the reduction of plasma pro-inflammatory cytokines and iNOS and NF-κB protein levels in the hippocampus (Figure 8). BDNF and CREB play prominent roles in mediating the therapeutic antidepressant effect of baicalein; however, elucidation of detailed signaling mechanisms requires further research.

Data Availability Statement:
The data presented in this study are available on request from the corresponding author. The data are not publicly available due to its proprietary nature.

Conflicts of Interest:
The authors declare no conflict of interest.

Data Availability Statement:
The data presented in this study are available on request from the corresponding author. The data are not publicly available due to its proprietary nature.

Conflicts of Interest:
The authors declare no conflict of interest.